Nov. 1 (Bloomberg) -- Shares of the following companies had unusual moves in U.S. trading. Stock symbols are in parentheses and prices are as of 4 p.m. in New York.
Financial shares tumbled on concern that a Greece referendum pledged by Prime Minister George Papandreou may threaten Europe’s bailout efforts. Morgan Stanley (MS US) declined 8 percent to $16.23. Citigroup Inc. (C US) slid 7.7 percent to $29.17. JPMorgan Chase & Co. (JPM US) slumped 5.9 percent to $32.71. Bank of America Corp. (BAC US) fell 6.3 percent to $6.40.
U.S. exchange operators fell after lawmakers said they will propose a tax on financial transactions such as stock and bond trades.
NYSE Euronext (NYX US) declined 6.8 percent to $24.76. Nasdaq OMX Group Inc. (NDAQ US) fell 2.8 percent to $24.36. CME Group Inc. (CME US) slumped 8.6 percent to $251.88.
Advanced Micro Devices Inc. (AMD US) sank 9.1 percent, the biggest decline since Oct. 3, to $5.30. The Sunnyvale, California-based maker of chips for Apple Inc.’s computers failed to persuade a U.S. judge to halt a patent dispute S3 Graphics Co. has against Apple at the U.S. International Trade Commission, according to a filing with the trade agency.
American Tower Corp. (AMT US) climbed 3.3 percent, the most since Aug. 23, to $56.92. The U.S. operator of mobile phone towers reported third-quarter revenue of $630.4 million, topping the average analyst estimate of $616.4 million.
Baker Hughes Inc. (BHI US) sank 7.7 percent, the most since Aug. 18, to $53.54. The oilfield contractor reported third-quarter earnings excluding some items of $1.18 a share, missing the average analyst estimate by 3 percent, according to Bloomberg data.
BankAtlantic Bancorp Inc. (BBX US) rose 111 percent, the most since 1996, to $5. BB&T Corp. (BBT US) is buying the bank for a premium of about $301 million over the net asset value of Bank Atlantic at the close of the deal, according to a statement. BB&T declined 3.7 percent to $22.48.
Clear Channel Outdoor Holdings Inc. (CCO US) erased 10 percent, the biggest drop since Aug. 8, to $9.88. The largest billboard advertising company reported third-quarter earnings of 1 cent a share, missing the average analyst estimate by 4 cents. The San Antonio-based company was cut to “neutral” from “buy” at Miller Tabak & Co.
Exelixis Inc. (EXEL US) plunged 40 percent to $4.62 for the biggest retreat in the Russell 2000 Index. The biotechnology company with no approved products failed to agree with U.S. regulators on special rules for a study of its experimental prostate cancer drug.
General Cable Corp. (BGC US) erased 20 percent to $22.31, the biggest decline in the Russell 1000 Index. The Highland Heights, Kentucky-based cable maker forecast revenue in the fourth quarter to be no more than $1.45 billion, falling short of the average analyst estimate of $1.55 billion.
Herbalife Ltd. (HLF US) lost 6.9 percent, the most since Aug. 8, to $58.03. The seller of nutritional and weight-loss supplements forecast 2012 earnings would be no more than $3.45 a share. Analysts project $3.54 a share, according to the average in a Bloomberg survey.
Interclick Inc. (ICLK US) rallied 21 percent to $8.94, the highest price since March 2008. Yahoo Inc., the U.S. Web portal that is exploring strategic options, agreed to buy the New York-based company for $270 million in cash to help advertisers reach online users with more targeted messages.
Leap Wireless International Inc. (LEAP US) jumped 11 percent, the most since Aug. 15, to $7.71. The prepaid wireless carrier gained reported an adjusted third-quarter loss of 69 cents a share, narrower than the 79-cent analyst estimate, according to data compiled by Bloomberg.
MetroPCS Communications Inc. (PCS US) fell 9.9 percent to $7.66, the biggest decline in the Standard & Poor’s 500 Index. The pay-as-you-go U.S. wireless carrier reported third-quarter profit that missed analysts’ estimates as subscriber growth slowed for the second consecutive quarter.
Pharmasset Inc. (VRUS US) rose 9.4 percent, the most since Sept 6, to $76.99. The pharmaceutical company initiated an Interferon-free Phase 3 trial of its hepatitis C treatment, PSI-7977, and said it expects to submit data for marketing approval in the U.S. and European Union in the second half of 2013.
Rogers Corp. (ROG US) declined 9.3 percent, the most since January 2010, to $39.17. The maker of components used by telephone, technology and defense companies forecast fourth-quarter revenue and sales that missed the average analyst estimate.
To contact the reporter on this story: Inyoung Hwang in New York at email@example.com
To contact the editor responsible for this story: Nick Baker at firstname.lastname@example.org